#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cortical dysplasia Chronic myelomonocytic leukaemia Epstein-Barr virus associated lymphoproliferative disorder Extra-osseous Ewing's sarcoma metastatic Bladder cancer Chronic graft versus host disease in skin Autologous haematopoietic stem cell transplant Diffuse large B-cell lymphoma refractory Facioscapulohumeral muscular dystrophy Gastrooesophageal cancer Cutaneous lupus erythematosus Adrenogenital syndrome Cutaneous T-cell lymphoma refractory Thymic carcinoma Exudative retinopathy More trials…

    Learn about Rare Diseases

    Hepatoblastoma – Basic Information Mucopolysaccharidosis III – Life with Disease Erdheim-Chester disease – Treatment Rett syndrome – Diagnostics Cystic fibrosis lung – Diagnostics Adrenocortical carcinoma – Trials in Disease Familial amyotrophic lateral sclerosis – Trials in Disease Haemophilia B with anti factor IX – Basic Information Myelodysplastic syndrome with excess blasts – Diagnostics Mantle cell lymphoma refractory – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Desvenlafaxine Benzoate Vancomycin Hydrochloride Clobetasol Propionate Ubamatamab Etripamil Dasatinib Acetylcysteine Agomelatine Minocycline Hydrochloride Levetiracetam Barium Sulfate Cagrilintide Zofenopril Calcium Rifabutin Bepirovirsen Bemarituzumab Pal1-15 Acetate Siplizumab Fluorometholone Brodalumab More therapies…

    Learn about Your Condition

    Thalassaemia Lung transplant rejection Becker's muscular dystrophy Pyoderma Radius fracture Primary hypogonadism Autism spectrum disorder Papulopustular rosacea Urticaria cholinergic Corneal graft rejection Cervix carcinoma recurrent Lupus nephritis Hypomagnesaemia Leiomyosarcoma KBG syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vitiligo

  • Efficacy and Safety of LY4005130 Compared with Placebo in Adults with Non‑Segmental Vitiligo

    Recruiting

    2 1
    Investigated Diseases:
    • Vitiligo
    Belgium Poland

  • A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

    Recruiting

    2 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Zasocitinib
    France Italy Poland Spain

  • Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

    Recruiting

    3 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Ruxolitinib
    Austria Belgium Bulgaria Denmark France Germany +6

  • Study of Ritlecitinib Combined with Narrow Band UVB Light Therapy Compared to Ritlecitinib Alone in Adults with Vitiligo

    Recruiting

    2 1 1 1
    France

  • Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hidradenitis
    • Neurodermatitis
    • Vitiligo
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    • Povorcitinib
    Austria Belgium Bulgaria Czechia Denmark France +7

  • Safety and efficacy of oral ACT-777991 in adults with non‑segmental vitiligo: a randomized, double‑blind, placebo‑controlled Phase 2a trial

    Not yet recruiting

    2 1
    Czechia Poland
1 2 3 4
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!